A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
This study is testing two medications, tucatinib and ado-trastuzumab emtansine, to see how well they control solid tumors that are HER2-positive and have spread to the brain. Researchers hope this combination can help patients by stopping or slowing down the growth of these cancer cells.
You might be eligible if you have a confirmed cancer with high levels of the HER2 protein that has spread to the brain. The brain tumors can be either newly found and untreated or previously treated, as long as they do not currently require immediate surgery or radiation.
Participants will receive study treatments consisting of targeted cancer therapies designed to attack HER2-positive cells. Your health team will closely monitor you and your tumors throughout the study to see how you respond.
This study is currently recruiting participants in Houston, Texas, United States. Joining the study means visiting the participating clinic for your treatments and check-ups.
- 1Tests a combination of two targeted therapies for HER2-positive cancers that have spread to the brain.
- 2Currently looking for participants at a location in Houston, Texas.
- 3Designed for patients whose brain tumors do not require immediate surgery or radiation.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.